WallStSmart

Merck & Company Inc (MRK)vsSomalogic Inc (SLGC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 80376% more annual revenue ($65.77B vs $81.72M). MRK leads profitability with a 13.6% profit margin vs -159.5%. MRK earns a higher WallStSmart Score of 53/100 (C-).

MRK

Buy

53

out of 100

Grade: C-

Growth: 3.3Profit: 8.5Value: 2.7Quality: 4.8
Piotroski: 2/9

SLGC

Avoid

29

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-15.8%)

Margin of Safety

-15.8%

Fair Value

$97.68

Current Price

$113.11

$15.43 premium

UndervaluedFair: $97.68Overvalued
SLGCOvervalued (-12.9%)

Margin of Safety

-12.9%

Fair Value

$1.86

Current Price

$9.89

$8.03 premium

UndervaluedFair: $1.86Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK4 strengths · Avg: 9.5/10
Market CapQuality
$277.02B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
36.9%10/10

Every $100 of equity generates 37 in profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

SLGC0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

MRK4 concerns · Avg: 3.3/10
P/E RatioValuation
31.5x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
3.432/10

Expensive relative to growth rate

SLGC4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$396.23M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-23.7%2/10

ROE of -23.7% — below average capital efficiency

Revenue GrowthGrowth
-47.1%2/10

Revenue declined 47.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin.

Bull Case : SLGC

SLGC has a balanced fundamental profile.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Bear Case : SLGC

The primary concerns for SLGC are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while SLGC is a turnaround play — different risk/reward profiles.

SLGC carries more volatility with a beta of 1.64 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (1.8B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (53/100 vs 29/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Somalogic Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

SomaLogic Inc. (SLGC) is a pioneering biotechnology company specializing in protein biomarker discovery and analysis, harnessing its proprietary SomaScan® platform to provide insights that advance precision medicine. By utilizing an extensive protein library, the company aims to develop sophisticated diagnostics and therapeutic applications across various health conditions, including cancer, cardiovascular diseases, and metabolic disorders. SomaLogic is positioned at the forefront of the biomarker industry, driving innovation in research and clinical settings while forming strategic partnerships to expand its reach and enhance the adoption of its technologies. With a strong focus on data-driven health solutions, SomaLogic is committed to improving patient outcomes and enabling personalized therapeutic strategies.

Want to dig deeper into these stocks?